Everolimus Tablet
Product Images NDC 67877-721

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 67877-721). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Evero-1 (Evero 1)

Packaging label for Everolimus Tablets 0.5 mg oral tablets by Ascend Laboratories, LLC. The label states the tablet strength of 0.5 mg per tablet, with contents of 6 blister cards of 10 tablets each. The label includes dispensing instructions, a barcode, and the designation Rx only.*

FDA Label Image

Evero-2 (Evero 2)

Packaging label for Everolimus Tablets 0.75 mg by Ascend Laboratories, LLC. The label indicates six blister cards with 10 tablets each. It includes dosage strength, manufacturing details, warning to dispense with medication guide, and directions to see package insert for dosage information. The label is primarily white with blue accents and contains a barcode.*

FDA Label Image

Evero-3 (Evero 3)

Everolimus 1 mg Tablets carton label from Ascend Laboratories, LLC. The label indicates oral tablets with each tablet containing 1 mg of everolimus. The packaging includes 6 blister cards with 10 tablets each. The label also includes directions to dispense with a medication guide, storage instructions, a barcode, and regulatory information.*

FDA Label Image

Evero-bottle-1mg-60s (Evero Bottle 1mg 60s)

Everolimus Tablets 1 mg per tablet oral dosage form label showing a 60-tablet package by Ascend Laboratories, LLC. The label includes storage instructions, dosage reference, manufacturer details, NDC code 67877-721-60, and a barcode. It emphasizes dispensing with a medication guide enclosed or provided separately.*

FDA Label Image

Evero-fig-1 (Evero Fig 1)

A line graph illustrating estimated glomerular filtration rate (eGFR MDRD 4) over time by visit window for two treatment groups: EVR + Reduced TAC and TAC Control. The y-axis shows eGFR values (mL/min/1.73m^2) ranging from 60 to 110, and the x-axis represents various visit windows from screening (Sc) through 24 months (M24). Data points include error bars indicating variability.*

FDA Label Image

Evero-str (Evero Str)

Chemical structure of Everolimus, depicting its molecular arrangement with various functional groups and ring systems, corresponding to the active ingredient in the Everolimus oral tablet by Ascend Laboratories, LLC.*

FDA Label Image

Evero- (Evero)

Packaging label for Everolimus Tablets 0.25 mg oral tablets by Ascend Laboratories, LLC. The carton design shows the product name, strength (0.25 mg per tablet), contents (6 blister cards of 10 tablets each), and distributor information. It includes dosing instructions, storage conditions, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.